20 results
DEF 14A
LYEL
Lyell Immunopharma, Inc.
28 Apr 22
Definitive proxy
4:11pm
determined that each of Mr. Rieflin, Ms. Friedman and Dr. Nabel is an “audit committee financial expert” within the meaning of
SEC regulations. Each
424B4
LYEL
Lyell Immunopharma, Inc.
18 Jun 21
Prospectus supplement with pricing info
12:00am
financial expert” within the meaning of SEC regulations. Each member of our audit committee can read and understand fundamental financial statements
S-1/A
hjwh uqxfyl
9 Jun 21
IPO registration (amended)
7:12am
S-1/A
EX-10.15
wwqq0
9 Jun 21
IPO registration (amended)
7:12am
S-1
EX-10.17
84yr2nhp6ah
25 May 21
IPO registration
5:28pm
S-1
EX-10.15
av6 4jp7q3z
25 May 21
IPO registration
5:28pm
S-1
zqcm7fu
25 May 21
IPO registration
5:28pm
S-1
EX-3.3
ahdwhb2igxr mz5diga
25 May 21
IPO registration
5:28pm
S-1
EX-10.9
m5cm6hp
25 May 21
IPO registration
5:28pm
S-1
EX-10.18
7hio 2cacn5do
25 May 21
IPO registration
5:28pm
DRS/A
45wcdgac1hd
12 May 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.9
ryqytknq5vj7pum
12 May 21
Draft registration statement (amended)
12:00am
DRS
EX-10.18
6ssxe3ao9xdxu2oqr
12 Apr 21
Draft registration statement
12:00am
DRS
EX-3.3
m9i cpdse6a
12 Apr 21
Draft registration statement
12:00am
DRS
ovl4iw99
12 Apr 21
Draft registration statement
12:00am
DRS
EX-10.17
piopo62 7er
12 Apr 21
Draft registration statement
12:00am
DRS
EX-10.15
9oloheljwjljicm9
12 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next